January 12, 2024 9:47 AM EST
A preliminary evaluate of unintended effects from well-liked medication used to deal with diabetes and weight problems reveals no hyperlink with suicidal ideas or actions, the U.S. Meals and Drug Administration stated Thursday.
However the company additionally stated officers can not definitively rule out that “a small threat could exist” and that they’re going to proceed to look into stories relating to greater than a dozen medication, together with Ozempic, Wegovy, and Mounjaro. Sufferers taking the medication ought to report any considerations to well being care suppliers, the FDA stated.
The evaluate follows a current federally funded research that confirmed that individuals taking semaglutide, the medicine in Ozempic and Wegovy, had a decrease threat of suicidal ideas than these taking different medication to deal with weight problems and diabetes. The evaluate got here after European regulators stated they have been investigating anecdotal stories that individuals taking semaglutide had ideas of self-harm.
“Our preliminary analysis has not discovered proof that use of those medicines causes suicidal ideas or actions,” the FDA report stated.
The company is analyzing stories associated to greater than a dozen medication permitted since 2005 which can be often known as GLP-1 receptor agonists. The medicines assist management blood sugar ranges and cut back the danger of coronary heart illness in folks with kind 2 diabetes. A number of the medication are additionally used to assist folks with weight problems or who’re chubby shed kilos.
